ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
MK-677 and my IGF-1 Levels
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="BigTex" data-source="post: 226086" data-attributes="member: 43589"><p>Will IGF-1 increase substantially by increasing the dose from 12.5 mg to 25 mg or even up to 50mg? Here is a very good study that investigated just that:</p><p></p><p>an M. Chapman, Ora H. Pescovitz, Gail Murphy, Theresa Treep, Kristine A. Cerchio, David Krupa, Barry Gertz, William J. Polvino, Emily H. Skiles, Suzan S. Pezzoli, Michael O. Thorner, Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults, <em>The Journal of Clinical Endocrinology & Metabolism</em>, Volume 82, Issue 10, 1 October 1997, Pages 3455–3463, <a href="https://doi.org/10.1210/jcem.82.10.4297" target="_blank">Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults*</a></p><p></p><p> Serum IGF-I and 24-h mean GH concentrations increased in all subjects after treatment with both 10 and 50 mg/day MK-677 <em>vs</em>. baseline. After treatment with 10 mg MK-677, IGF-I concentrations increased 52 ± 20% (65± 6 to 99 ± 9 μg/L, geometric mean ± intrasubject SE, <em>P</em> ≤ 0.05 <em>vs</em>. baseline), and 24 h mean GH concentrations increased 79 ± 19% (0.14 ± 0.01 to 0.26 ± 0.02 μg/L, <em>P</em> ≤ 0.05 <em>vs</em>. baseline). Following treatment with 50 mg MK-677, IGF-I concentrations increased 79 ± 9% (84 ± 3 to 150 ± 6 μg/L, <em>P</em> ≤ 0.05 <em>vs</em>. baseline) and 24-h mean GH concentrations increased 82 ± 29% (0.21 ± 0.02 to 0.39 ± 0.04μ g/L, <em>P</em> ≤ 0.05 <em>vs</em>. baseline), respectively. Serum IGF binding protein-3 concentrations increased with both 10 mg (1.2 ± 0.1 to 1.7 ± 0.1 μg/L, <em>P</em> ≤ 0.05) and 50 mg MK-677 (1.7 ± 0.1 to 2.2 ± 0.2 μg/L, <em>P</em> ≤ 0.05). The GH response to MK-677 was greater in subjects who were the least GH/IGF-I deficient at baseline; by linear regression analysis the increase in 24-h mean GH concentration was positively related to both baseline 24-h mean GH concentration (r = 0.81, <em>P</em> = 0.009) and baseline IGF-I (r = 0.79, <em>P</em> = 0.01) for 10 mg MK-677. IGF-I responses were not significantly related to any baseline measurement. Fasting and postprandial insulin and postprandial glucose increased significantly after MK-677 treatment, and the clinical significance of these changes will need to be assessed in longer term studies. Oral administration of such GHRP-mimetic compounds may have a role in the treatment of GH deficiency of childhood onset.</p><p></p><p>So with 10mg. GH increased about 79%, IGF-1 increased about 52%</p><p>50mg GH increased 82% and IGF-1 increased about 79%</p><p></p><p><img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/82/10/10.1210_jcem.82.10.4297/2/m_eg1074297005.jpeg?Expires=1657482419&Signature=xWR5kF~1jLRdFPVPHKek1v96DbpjAjAEyDOkkvxreGX0bFCujdRuudDIRJvMCVyQiNZKRRdUNgVA3jJVM0HZJjAu87s171mdegeylOeiUZPoolPnBfVMbGTkbaj4mjmnvHR5NJzZs4ZDO47LZYcPURW3F~guY~fTe3zbHmP0qV63JxiIQ2n-HWE-gl1PREs6UC0t~9nexH2NbuikrblbZo~a-ESzIjaDq0lNbT5VK6FbXg~rPnI7mvXJhdOId3oHGdpv2nOu72POBVDMwqD~MalPyNGRuyocpwqD1R9bU69yanzfDSyDBei6uZK~CrZFP3~uSJdnn73DjGEFTncjNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="bbImage" alt="" data-url="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/82/10/10.1210_jcem.82.10.4297/2/m_eg1074297005.jpeg?Expires=1657482419&Signature=xWR5kF~1jLRdFPVPHKek1v96DbpjAjAEyDOkkvxreGX0bFCujdRuudDIRJvMCVyQiNZKRRdUNgVA3jJVM0HZJjAu87s171mdegeylOeiUZPoolPnBfVMbGTkbaj4mjmnvHR5NJzZs4ZDO47LZYcPURW3F~guY~fTe3zbHmP0qV63JxiIQ2n-HWE-gl1PREs6UC0t~9nexH2NbuikrblbZo~a-ESzIjaDq0lNbT5VK6FbXg~rPnI7mvXJhdOId3oHGdpv2nOu72POBVDMwqD~MalPyNGRuyocpwqD1R9bU69yanzfDSyDBei6uZK~CrZFP3~uSJdnn73DjGEFTncjNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" style="" /></p><p> </p><p>IGFBP-3 was also greatly increased over baseline. IGFBP-3 is the main carrier of somatomedin C (also called insulin-like growth factor-1, or IGF-1) in the body.</p><p></p><p><img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/82/10/10.1210_jcem.82.10.4297/2/m_eg1074297006.jpeg?Expires=1657482419&Signature=RbdCd-WzoS~c~Gpc51QBbNqkmIMsBK1s1c8V5Dfu6n566EWmshAuUSYKq7X8ssSTr-VcjWEHy8ECir6mI2Yvz5CPmEOZ7INmMytiF7CAu15Ox0haOO43g-fNFb4Ed6m6eWNvWmNt8JJiAnjRcshX24WU3xcFoBBeH5FPOuO3~fa8ubKF~z2ULTHS5FUlhSt-H~spvl-LJWcq84as~0rFppLfauVzVgAjJAEhY0038eGTfFAq9EGPQS4ieIgWhQhjJyXn8wqCHZkvei3epQ8RO6P0A8wyxyUajtBwM78H72tUvsQ-sZGouhsFkGxAXoYY708G5Xq6gJN4VFhIksPhxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="bbImage" alt="" data-url="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/82/10/10.1210_jcem.82.10.4297/2/m_eg1074297006.jpeg?Expires=1657482419&Signature=RbdCd-WzoS~c~Gpc51QBbNqkmIMsBK1s1c8V5Dfu6n566EWmshAuUSYKq7X8ssSTr-VcjWEHy8ECir6mI2Yvz5CPmEOZ7INmMytiF7CAu15Ox0haOO43g-fNFb4Ed6m6eWNvWmNt8JJiAnjRcshX24WU3xcFoBBeH5FPOuO3~fa8ubKF~z2ULTHS5FUlhSt-H~spvl-LJWcq84as~0rFppLfauVzVgAjJAEhY0038eGTfFAq9EGPQS4ieIgWhQhjJyXn8wqCHZkvei3epQ8RO6P0A8wyxyUajtBwM78H72tUvsQ-sZGouhsFkGxAXoYY708G5Xq6gJN4VFhIksPhxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" style="" /></p><p></p><p>MK-677 treatment was generally well tolerated and no symptoms developed that were definitely attributed to study drug. There were no serious adverse events during this study, and no subjects were discontinued or had treatment interrupted because of an adverse experience.</p><p></p><p><strong>Something to consider: </strong> IGF-I and GH concentrations were significantly increased after 2 weeks treatment with oral MK-677 in healthy older subjects. Moreover, IGF-I concentrations increased further between 2–4 weeks of treatment, indicating that the full effect of MK-677 on IGF-I concentrations took longer than 2 weeks to develop, and that significant stimulation of the GH/IGF-I axis was sustained for at least a month</p></blockquote><p></p>
[QUOTE="BigTex, post: 226086, member: 43589"] Will IGF-1 increase substantially by increasing the dose from 12.5 mg to 25 mg or even up to 50mg? Here is a very good study that investigated just that: an M. Chapman, Ora H. Pescovitz, Gail Murphy, Theresa Treep, Kristine A. Cerchio, David Krupa, Barry Gertz, William J. Polvino, Emily H. Skiles, Suzan S. Pezzoli, Michael O. Thorner, Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults, [I]The Journal of Clinical Endocrinology & Metabolism[/I], Volume 82, Issue 10, 1 October 1997, Pages 3455–3463, [URL="https://doi.org/10.1210/jcem.82.10.4297"]Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults*[/URL] Serum IGF-I and 24-h mean GH concentrations increased in all subjects after treatment with both 10 and 50 mg/day MK-677 [I]vs[/I]. baseline. After treatment with 10 mg MK-677, IGF-I concentrations increased 52 ± 20% (65± 6 to 99 ± 9 μg/L, geometric mean ± intrasubject SE, [I]P[/I] ≤ 0.05 [I]vs[/I]. baseline), and 24 h mean GH concentrations increased 79 ± 19% (0.14 ± 0.01 to 0.26 ± 0.02 μg/L, [I]P[/I] ≤ 0.05 [I]vs[/I]. baseline). Following treatment with 50 mg MK-677, IGF-I concentrations increased 79 ± 9% (84 ± 3 to 150 ± 6 μg/L, [I]P[/I] ≤ 0.05 [I]vs[/I]. baseline) and 24-h mean GH concentrations increased 82 ± 29% (0.21 ± 0.02 to 0.39 ± 0.04μ g/L, [I]P[/I] ≤ 0.05 [I]vs[/I]. baseline), respectively. Serum IGF binding protein-3 concentrations increased with both 10 mg (1.2 ± 0.1 to 1.7 ± 0.1 μg/L, [I]P[/I] ≤ 0.05) and 50 mg MK-677 (1.7 ± 0.1 to 2.2 ± 0.2 μg/L, [I]P[/I] ≤ 0.05). The GH response to MK-677 was greater in subjects who were the least GH/IGF-I deficient at baseline; by linear regression analysis the increase in 24-h mean GH concentration was positively related to both baseline 24-h mean GH concentration (r = 0.81, [I]P[/I] = 0.009) and baseline IGF-I (r = 0.79, [I]P[/I] = 0.01) for 10 mg MK-677. IGF-I responses were not significantly related to any baseline measurement. Fasting and postprandial insulin and postprandial glucose increased significantly after MK-677 treatment, and the clinical significance of these changes will need to be assessed in longer term studies. Oral administration of such GHRP-mimetic compounds may have a role in the treatment of GH deficiency of childhood onset. So with 10mg. GH increased about 79%, IGF-1 increased about 52% 50mg GH increased 82% and IGF-1 increased about 79% [IMG]https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/82/10/10.1210_jcem.82.10.4297/2/m_eg1074297005.jpeg?Expires=1657482419&Signature=xWR5kF~1jLRdFPVPHKek1v96DbpjAjAEyDOkkvxreGX0bFCujdRuudDIRJvMCVyQiNZKRRdUNgVA3jJVM0HZJjAu87s171mdegeylOeiUZPoolPnBfVMbGTkbaj4mjmnvHR5NJzZs4ZDO47LZYcPURW3F~guY~fTe3zbHmP0qV63JxiIQ2n-HWE-gl1PREs6UC0t~9nexH2NbuikrblbZo~a-ESzIjaDq0lNbT5VK6FbXg~rPnI7mvXJhdOId3oHGdpv2nOu72POBVDMwqD~MalPyNGRuyocpwqD1R9bU69yanzfDSyDBei6uZK~CrZFP3~uSJdnn73DjGEFTncjNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA[/IMG] IGFBP-3 was also greatly increased over baseline. IGFBP-3 is the main carrier of somatomedin C (also called insulin-like growth factor-1, or IGF-1) in the body. [IMG]https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/82/10/10.1210_jcem.82.10.4297/2/m_eg1074297006.jpeg?Expires=1657482419&Signature=RbdCd-WzoS~c~Gpc51QBbNqkmIMsBK1s1c8V5Dfu6n566EWmshAuUSYKq7X8ssSTr-VcjWEHy8ECir6mI2Yvz5CPmEOZ7INmMytiF7CAu15Ox0haOO43g-fNFb4Ed6m6eWNvWmNt8JJiAnjRcshX24WU3xcFoBBeH5FPOuO3~fa8ubKF~z2ULTHS5FUlhSt-H~spvl-LJWcq84as~0rFppLfauVzVgAjJAEhY0038eGTfFAq9EGPQS4ieIgWhQhjJyXn8wqCHZkvei3epQ8RO6P0A8wyxyUajtBwM78H72tUvsQ-sZGouhsFkGxAXoYY708G5Xq6gJN4VFhIksPhxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA[/IMG] MK-677 treatment was generally well tolerated and no symptoms developed that were definitely attributed to study drug. There were no serious adverse events during this study, and no subjects were discontinued or had treatment interrupted because of an adverse experience. [B]Something to consider: [/B] IGF-I and GH concentrations were significantly increased after 2 weeks treatment with oral MK-677 in healthy older subjects. Moreover, IGF-I concentrations increased further between 2–4 weeks of treatment, indicating that the full effect of MK-677 on IGF-I concentrations took longer than 2 weeks to develop, and that significant stimulation of the GH/IGF-I axis was sustained for at least a month [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
MK-677 and my IGF-1 Levels
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top